Locally advanced unresectable or metastatic solid tumors that have failed at least two lines of therapy (one of which must be targeted therapy)
At least one measurable lesion as defined by RECIST v1.1 criteria
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
Adequate hematologic and renal, hepatic and cardiac function
Oxygen saturation via pulse oximeter ≥92% at rest on room air
You may not be if
Prior treatment with a genetically modified cell therapy product targeting EGFR
History of allogeneic transplantation
Subjects with active CNS metastases
History or presence of clinically relevant Central Nervous System (CNS) disorder (e.g. epilepsy)
Clinically significant active infection
Human Immunodeficiency Virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.
History of malignancies with the exception of certain treated malignancies with no evidence of disease.
Primary immunodeficiency disorder
Pregnant or lactating female
Any medical, psychological, familial, or sociological conditions that, in the opinion of the Investigator or Sponsor Medical Monitor, would impair the ability of the subject to receive study treatment or comply with study requirements, including understanding and rendering of informed consent
Clareo Health | ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
